|
|
Profile
|
Delegates :
Takashi Hashimoto |
|
Incorporated :
July 29 , 2021 |
Paid in Capital :
1 Million yen |
Employees :
4 人 |
Address :
1-4-3 Asahimachi, Abeno-ku, Osaka City. OSAKA
〒545-0051
|
TEL/FAX :
06-6646-6630 / 06-6646-6630 |
URL：
|
Attachment :
|
Mission/Background :
AIBD Labs Inc. is an Osaka Metropolitan University-approved venture company, specialized in diagnosis of autoimmune bullous disease. Autoimmune bullous diseases cause blistering by autoantibodies to various autoantigens of the skin, and classified into 50 different subtypes. AIBD Labs Inc. has developed a comprehensive diagnostic system for all autoimmune blistering diseases. The aim is to contribute to the world through rapid and accurate diagnosis using this diagnostic system. |
|
Technology & Business
|
Diagnostic tests for autoimmune bullous disease that we have independently developed so far.
(1) Various indirect fluorescence methods
Substrate: normal skin sections, 1M NaCl-split-skin sections, rat bladder sections, monkey esophagus sections
(2) Various ELISA methods
Original ELISA methods: Dsc1, Dsc2, Dsc3.
(3) Various immunoblotting methods
Substrate: Human epidermal extracts
Human dermal extract
BP180 NC16a domain recombinant protein
BP180 C-terminal domain recombinant protein
Purified laminin 332 (laminin 332 recombinant protein)
Concentrated culture supernatant of HaCaT cells
Hemidesmosome-rich fraction
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Comprehensive diagnostic test system for autoimmune bullous diseases
|
Launched
|
We perform various diagnostic methods to diagnose all autoimmune blistering diseases and contribute to appropriate treatment.
|
Establish or share testing facilities (laboratories)
|
AI-based automated diagnosis system for immunofluorescence for diagnosis of autoimmune blistering
|
Preclinical
|
Automated diagnosis of immunofluorescence methods for autoimmune blistering using a programme created using AI (deep learning).
|
Until now, immunofluorescence is determined visually by inspectors, but this programme enables accurate and uniform diagnosis.
|
Detection of anti-transglutaminase 1 autoantibodies in paraneoplastic pemphigus
|
Discovery
|
Contribute to the diagnosis of paraneoplastic pemphigus using the detection of anti-transglutaminase 1 autoantibodies
|
We are attempting to improve the method to a more general test
|
|
|
|
|
|
|
|
|
|
Highlights
|
We developed new diagnostic methods, i.e., HD-rich fraction immunoblotting, AI-based automated diagnosis of immunofluorescence, and anti-transglutaminase 1 autoantibody detection kit. The latter two have been patented.
To set up a testing facility (laboratory) in Nagpur, India, we visited to India and consulted with local officials.
Agreements have been obtained with three companies for the provision of test kits, and discussions are underway for the sharing of testing facilities (laboratories).
|
|
Hot news
|
Currently, more than 20 different tests are needed to diagnose all autoimmune bullous diseases. We are planning to use only three tests: i.e., immunoblotting of HD-rich fraction, Biochip methods and ELISA for desmocollins for the comprehensive diagnoses.
|
|
Alliance strategy
|
We would like to form an alliance between AIBD Laboratories, Inc. and other companies for the sharing of test facility/laboratory that will carry out these various tests.
We would like to cooperate with the established companies of clinical laboratory tests in the shipment of the test samples.
|
|
|